No bubble is my thinking as well. I think how we value biotech is being re-rated as we speak. EPS & profit are clear drivers once Drug/Device approval is reached. Anyone thinking $ARDX is undervalued needs to look at profit, EPS, and maybe 17 years with the same clown running the show. Who cares if scripts are up if it’s unprofitable? I am counting on HFs more & more to deliver unforced errors. Bubbles help reset the narrative…or do they?
View on X ↗